ATAGI recommendations on the use of Spikevax (Moderna) COVID-19 vaccine in children aged 6 to 11 years
Following the TGA’s provisional approval, ATAGI has put forth a guideline that recommends the use of Moderna’s COVID-19 vaccine (Spikevax) in children aged 6 to 11 years.
Clinical data supports that Spikevax produces a strong immune response and reduces the likelihood of children in this cohort developing COVID-19.
This statement addresses the recommendations, considerations and rationale for the use of Moderna’s COVID-19 vaccine in children aged 6 to 11.
पूरा बयान पढ़ने के लिए नीचे दिए गए लिंक का अनुसरण करें।
बातचीत: मॉडर्ना का टीका अब 6 से 11 साल के बच्चों के लिए उपलब्ध है। यहां माता-पिता को जानने की जरूरत है
मॉडर्न COVID-19 वैक्सीन को अब 6 से 11 साल की उम्र के बच्चों में इस्तेमाल के लिए मंजूरी मिल गई है। ऑस्ट्रेलिया के प्राइमरी-स्कूल जाने वाले आधे से भी कम बच्चों को कोविड वैक्सीन की पहली खुराक मिली है, मॉडर्न के कोविड वैक्सीन की मंज़ूरी माता-पिता को अपने बच्चों को गंभीर बीमारी से बचाने का एक अतिरिक्त अवसर प्रदान करती है।
किडकोव क्लिनिकल परीक्षण के बाद, यह लेख 6 से 11 साल के समूह में मॉडर्न के COVID-19 वैक्सीन के उपयोग के लिए चल रही सुरक्षा और प्रभावकारिता के साथ-साथ विचारों और प्रशासनिक सिफारिशों की पड़ताल करता है।
पूरा लेख पढ़ने के लिए, नीचे दिए गए लिंक का अनुसरण करें।
ATAGI update following weekly COVID-19 meeting – 16 February 2022
ATAGI held their weekly meeting on Wednesday 16 February to discuss the latest developments and recommendations relating to COVID-19 immunisations.
The meeting addressed the use of Moderna’s COVID-19 vaccine in children aged 6 to 11 years, as well as, the use of Novavax’s COVID-19 vaccine as a booster and recommendations regarding the vaccine dose interval for children.
To read the full update, follow the link below:
ATAGI update following weekly COVID-19 meeting – 16 February 2022
मॉडर्न का COVID-19 वैक्सीन (SPIKEVAX) 6 साल और उससे अधिक उम्र के व्यक्तियों में उपयोग के लिए अस्थायी रूप से स्वीकृत
थेराप्यूटिक गुड्स एडमिनिस्ट्रेशन (TGA) ने 6 साल और उससे अधिक उम्र के व्यक्तियों में उपयोग के लिए मॉडर्न COVID-19 वैक्सीन, SPIKEVAX को अस्थायी रूप से मंजूरी दे दी है। यह TGA द्वारा मॉडर्न को 3 सितंबर 2021 को 12 वर्ष और उससे अधिक आयु के व्यक्तियों में SPIKEVAX के उपयोग के लिए और 7 दिसंबर 2021 को 18 वर्ष और उससे अधिक उम्र के वयस्कों में SPIKEVAX बूस्टर खुराक के लिए दी गई अनंतिम स्वीकृति के बाद है।
टीजीए ने किडकोव क्लिनिकल परीक्षण के बाद डेटा का सावधानीपूर्वक मूल्यांकन किया, जिसमें अमेरिका और कनाडा में 6 से 11 वर्ष की आयु के 4,000 प्रतिभागियों को शामिल किया गया था, यह दर्शाता है कि बच्चों में टीके के लिए प्रतिरक्षा प्रतिक्रिया वृद्धावस्था समूहों में देखी गई समान थी।
इसके अलावा, नैदानिक आंकड़ों से पता चला है कि बच्चों में सुरक्षा प्रोफाइल वयस्कों के समान ही है। इस उम्र के समूह में सबसे लगातार दुष्प्रभाव अल्पावधि और गैर-गंभीर थे। इनमें इंजेक्शन वाली जगह पर दर्द, लालिमा और/या सूजन, बगल (कमर) में सूजन या कोमलता, थकान, सिरदर्द, बुखार और मांसपेशियों में दर्द शामिल हैं।
इस आयु वर्ग के लिए SPIKEVAX के रोलआउट पर आगे की सलाह सरकार को ऑस्ट्रेलियन टेक्निकल एडवाइजरी ग्रुप ऑन इम्यूनाइजेशन (ATAGI) द्वारा प्रदान की जाएगी।
बयान को पूरा पढ़ने के लिए कृपया नीचे दिए गए लिंक पर क्लिक करें:
CDC: Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19–Associated Hospitalization in Infants Aged <6 Months — 17 States, July 2021–January 2022
A recent CDC report revealed that maternal completion of a 2-dose primary mRNA COVID-19 vaccine course during pregnancy reduced the risk of COVID-19 hospitalisation amongst infants <6 months. Data revealed that of 176 COVID-19 related paediatric hospitalisations, 148 (84%) of infants were born to mothers who were not vaccinated during pregnancy.
Transplacental transfer of SARS-CoV2-specific antibodies that may provide protection to infants is evident in women vaccinated during the later stages of pregnancy. Detectable COVID-19 antibodies were also present in breast milk, indicating a transfer of maternal antibodies to the baby.
This study demonstrates that mRNA COVID-19 vaccination in pregnant and breast-feeding women is safe and effective and provides increased protection to the baby.
To read the report in full, follow the link below:
CDC: Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19–Associated Hospitalization in Infants Aged <6 Months — 17 States, July 2021–January 2022
Contemporary Pediatrics: Novavax pediatric COVID-19 vaccine trial yields positive results
Novavax’s protein-based recombinant nanoparticle COVID-19 vaccine NVC-CoV2373 has demonstrated an 80% overall efficacy in paediatric trials against the Delta variant.
The paediatric trial included 2247 adolescent participants between the ages of 12 to 17 years, of diverse racial and ethnic backgrounds, across 73 sites in the United States.
“We are encouraged by the results in this adolescent population given the ongoing need for alternative vaccine options for COVID-19,” said Filip Dubovsky, MD, Chief Medical Officer, Novavax, in the statement.
To read the full press release, follow the link below:
Novavax pediatric COVID-19 vaccine trial yields positive results
The Washington Post: Coronavirus vaccine for young children further delayed as FDA reverses course, says it will wait for data on three doses
The Food and Drug Administration (FDA) have announced it won’t make a decision on whether to authorise a COVID-19 vaccine for children younger than 5 until data on a third dose becomes available.
The vaccine trial that commenced on 20वां January, was designed to test the safety and efficacy of a lower dose of vaccine and was reported to include 3,900 children between the ages of 6 months and 4 years.
To understand if two doses would provide sufficient protection in children younger than 5, Pfizer and BioNTech have been testing two 3-microgram doses, a small fraction of the adult dose. Smaller doses are expected to trigger an equivalent immune response in children, indicating strong protection.
With the study advancing at a rapid pace, Pfizer and BioNTech will opt to wait for the three-dose data suggesting it may provide a higher level of protection in this age group.
Click on the link below to read the article in full:
The Washington Post: Coronavirus vaccine for young children further delayed as FDA reverses course, says it will wait for data on three doses
CEPI opens Call to develop heat-stable vaccine tech for use against epidemic and pandemic threats
The Coalition for Epidemic Preparedness Innovations (CEPI) has launched a $17.5 million initiative to improve the thermostability of current and future vaccines.
Currently, cold chain requirements are one of the leading causes of global vaccine wastage. Improving the thermostability of vaccines will work to improve global access, especially in low-income countries.
CEPI’s Acting Director of Vaccine Manufacturing and Supply Chain, Ingrid Kromann said: “We’re really looking to see a step change in the way that some of these vaccines can be stored and delivered.”
पूरा लेख पढ़ने के लिए, नीचे दिए गए लिंक का अनुसरण करें:
CEPI opens Call to develop heat-stable vaccine tech for use against epidemic and pandemic threats
WHO: Commonwealth and WHO to strengthen cooperation on health, including access to vaccines
The Commonwealth Secretariat and the World Health Organization (WHO) signed a Memorandum of Understanding (MoU) which works to strengthen their ongoing collaboration and commitment towards improving vaccine equity as well as a wide range of public health issues.
The Rt. Hon. Patricia Scotland QC said: “Equitable access to vaccines is the world’s most pressing political, economic, social and moral priority. Without effective and prompt action on vaccines, we face a never-ending global health crisis that will reduce all of our wealth and security”
The ongoing COVID-19 pandemic has exposed the need for a stronger more accessible global health system, especially in lower-income countries.
पूरा बयान पढ़ने के लिए नीचे दिए गए लिंक का अनुसरण करें।
Commonwealth and WHO to strengthen cooperation on health, including access to vaccines
ATAGI recommendations for use of Pfizer COVID-19 vaccine as a booster dose in adolescents aged 16-17 years
The Australian Technical Advisory Group on Immunisation (ATAGI) has made recommendations for use of Pfizer COVID-19 vaccine as a booster dose in adolescents aged 16-17 years.
Evidence demonstrates that waning of protection against the Omicron variant occurs after a two-dose primary vaccination schedule and a booster dose is required to increase protection against infection and severe disease.
This statement addresses the safety, efficacy and epidemiological considerations.
Follow the link below to read the recommendations in full:
ATAGI recommendations for use of Pfizer COVID-19 vaccine as a booster dose in adolescents aged 16-17 years.